Latest Vertex Pharmaceuticals Stories
BETHESDA, Md., April 19, 2013 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco(TM) in combination with another potential CF therapy, VX-661. The results showed a significant improvement in lung function in people with two copies of the most common CF mutation, Delta F508, who took the...
First Drug to Treat the Cystic Fibrosis Defect was Developed in Collaboration With Cystic Fibrosis Foundation BETHESDA, Md., Oct. 25, 2012 /PRNewswire-USNewswire/ -- Kalydeco(TM), the first drug to treat the underlying cause of cystic fibrosis, has won The Wall Street Journal's 2012 Technology Innovation Award in the Medicine and Biotech category. The awards recognize technological breakthroughs that are game-changers or have a wide impact in their field and beyond. Kalydeco was...
NEW YORK, Oct. 11, 2012 /PRNewswire/ -- (Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO) Alliance Financial CorporationLevi & Korsinsky is investigating the Board of Directors of Alliance Financial Corporation (Nasdaq: ALNC) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to NBT Bancorp Inc. (NasdaqGS: NBTB) for approximately $48 per share in NBT stock. At least one analyst set a price target...
SAN DIEGO, July 16, 2012 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of a lease extension with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for approximately 81,200 square feet at the company's Torreyana Road property located in the heart of the Torrey Pines submarket of San Diego, California. The lease now extends through December 31, 2018. Ranked as the top place to work in the life science industry by Science magazine in 2011, Vertex...
BEND, Oregon, November 9 /PRNewswire/ -- Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA. Through this new collaboration, Vertex will utilize Bend's formulation development and...
Researchers have reported success with the addition of the anti-viral drug telaprevir to standard treatment of hepatitis C.A team of researchers at the Duke Clinical Research Institute (DCRI) found that the duration of hepatitis C could be cut in half with the addition of telaprevir."Standard treatment for the most common type of hepatitis C is 48 weeks of a combination of two drugs, peginterferon alfa-2a and ribavirin, which cures less than half of patients and has significant side...
PRINCETON, N.J., March 12 /PRNewswire-FirstCall/ -- BullMarket.com (http://www.bullmarket.com), an online investment newsletter focused on long-term growth and income-generating stocks, has provided subscribers with updated coverage of several biotech stocks, including Amgen (Nasdaq: AMGN), Gilead Sciences (Nasdaq: GILD), Celgene (Nasdaq: CELG), Genzyme (Nasdaq: GENZ), and Vertex Pharmaceuticals (Nasdaq: VRTX). All paid and trial subscribers to BullMarket.com can now receive immediate...
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Freda C. Lewis-Hall, M.D. as Executive Vice President, Medicines Development. Dr. Lewis-Hall joins Vertex from Bristol-Myers Squibb, Incorporated, and has extensive leadership experience across multiple functional areas in the pharmaceutical industry. At Vertex, Dr. Lewis-Hall will be responsible for Regulatory Affairs, Clinical and Non-clinical Development, Medical Affairs and Commercial Development. Dr....
